Oncostatin M promotes lipolysis in white adipocytes.


Journal

Adipocyte
ISSN: 2162-397X
Titre abrégé: Adipocyte
Pays: United States
ID NLM: 101567863

Informations de publication

Date de publication:
12 2022
Historique:
pubmed: 10 5 2022
medline: 20 5 2022
entrez: 9 5 2022
Statut: ppublish

Résumé

Oncostatin M (OSM) is a member of the glycoprotein 130 cytokine family that is involved in chronic inflammation and increased in adipose tissue under obesity and insulin resistance. OSM was shown to inhibit adipogenesis, suppress browning, and contribute to insulin resistance in cultured white adipocytes. In contrast, OSM may have a metabolically favourable role on adipocytes in mouse models of obesity and insulin resistance. However, a putative role of OSM in modulating lipolysis has not been investigated in detail to date. To address this, cultured white adipocytes of mouse or human origin were exposed to 10 or 100 ng/ml of OSM for various time periods. In murine 3T3-L1 cells, OSM stimulation directly activated hormone-sensitive lipase (HSL) and other players of the lipolytic machinery, and dose-dependently increased free fatty acid and glycerol release. In parallel, OSM attenuated insulin-mediated suppression of lipolysis and induced phosphorylation of serine-residues on the insulin receptor substrate-1 (IRS1) protein. Key experiments were verified in a second murine and a human adipocyte cell line. Inhibiton of extracellular signal-regulated kinase (ERK)-1/2 activation, abolished OSM-mediated HSL phosphorylation and lipolysis. In conclusion, OSM signalling directly promotes lipolysis in white adipocytes in an ERK1/2-dependent manner.

Identifiants

pubmed: 35531859
doi: 10.1080/21623945.2022.2075129
pmc: PMC9116407
doi:

Substances chimiques

Fatty Acids 0
IRS1 protein, human 0
Insulin Receptor Substrate Proteins 0
Irs1 protein, mouse 0
Oncostatin M 106956-32-5
Glycerol PDC6A3C0OX

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

315-324

Références

Anat Sci Int. 2018 Mar;93(2):169-176
pubmed: 29103176
J Biol Chem. 1999 Apr 23;274(17):12017-22
pubmed: 10207024
Int J Biochem Cell Biol. 2007;39(2):439-49
pubmed: 17081797
J Biol Chem. 1997 Sep 26;272(39):24183-90
pubmed: 9305869
Obes Facts. 2008;1(4):184-9
pubmed: 20054179
Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E155-62
pubmed: 15383370
Endocrine. 2008 Jun;33(3):261-9
pubmed: 19016005
Cell Metab. 2017 Nov 7;26(5):764-777.e5
pubmed: 28988822
Nutr Res Rev. 2014 Jun;27(1):63-93
pubmed: 24872083
Mol Metab. 2021 Dec;54:101341
pubmed: 34547509
Front Immunol. 2021 Mar 29;11:612013
pubmed: 33854494
J Clin Endocrinol Metab. 2014 Feb;99(2):E217-25
pubmed: 24297795
Obesity (Silver Spring). 2017 Jan;25(1):85-93
pubmed: 27706920
Cytokine Growth Factor Rev. 2015 Oct;26(5):545-58
pubmed: 26198770
Biochim Biophys Acta. 2013 Oct;1831(10):1533-41
pubmed: 23500888
Cells. 2021 Nov 17;10(11):
pubmed: 34831427
J Biol Chem. 2014 May 16;289(20):13821-37
pubmed: 24695736
Cell Metab. 2017 Nov 7;26(5):753-763.e7
pubmed: 28988821
Endocrinology. 1994 Jul;135(1):141-7
pubmed: 8013346
J Cell Biochem. 2003 Aug 15;89(6):1077-86
pubmed: 12898507
J Biol Chem. 2016 Aug 12;291(33):17066-76
pubmed: 27325693
Obesity (Silver Spring). 2018 Sep;26(9):1439-1447
pubmed: 30226002
Diabetologia. 2015 Aug;58(8):1868-76
pubmed: 25972231
Trends Endocrinol Metab. 2014 May;25(5):255-62
pubmed: 24731595
J Biol Chem. 2013 Jul 26;288(30):21861-75
pubmed: 23760275
Nature. 2011 Nov 20;480(7375):104-8
pubmed: 22101429
J Biol Chem. 2000 Mar 24;275(12):9047-54
pubmed: 10722755
Nat Rev Mol Cell Biol. 2006 Feb;7(2):85-96
pubmed: 16493415
J Biol Chem. 2001 Nov 30;276(48):45456-61
pubmed: 11581251
Int J Obes Relat Metab Disord. 2001 Jan;25(1):8-15
pubmed: 11244452
J Lipid Res. 2014 Dec;55(12):2634-43
pubmed: 25351614
Nat Med. 2001 Aug;7(8):941-6
pubmed: 11479627
Am J Physiol Endocrinol Metab. 2015 Aug 1;309(3):E205-13
pubmed: 26058863
Circulation. 2005 Apr 19;111(15):1938-45
pubmed: 15837947
Trends Immunol. 2019 Sep;40(9):857-872
pubmed: 31399336
J Biol Chem. 2002 Jan 11;277(2):1085-91
pubmed: 11694522
Arch Endocrinol Metab. 2020 Feb;64(1):38-44
pubmed: 31576964
ISRN Inflamm. 2013 Dec 08;2013:512103
pubmed: 24381786
J Biol Chem. 2006 Dec 8;281(49):37913-20
pubmed: 17028188

Auteurs

Pim P van Krieken (PP)

Division of Pediatric Endocrinology and Diabetology, University Children's Hospital, University of Zurich, Zurich, Switzerland.
Children's Research Center, University Children's Hospital, University of Zurich, Zurich, Switzerland.

Julian Roos (J)

Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.

Pamela Fischer-Posovszky (P)

Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.

Stephan Wueest (S)

Division of Pediatric Endocrinology and Diabetology, University Children's Hospital, University of Zurich, Zurich, Switzerland.
Children's Research Center, University Children's Hospital, University of Zurich, Zurich, Switzerland.

Daniel Konrad (D)

Division of Pediatric Endocrinology and Diabetology, University Children's Hospital, University of Zurich, Zurich, Switzerland.
Children's Research Center, University Children's Hospital, University of Zurich, Zurich, Switzerland.
Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH